Tenaya Therapeutics(TNYA)
$0.30-0.01 (-2.61%)
TNYA
Tenaya Therapeutics financials statements
$0.30
At close:-0.01 (-2.61%)
Want to see TNYA full AI Analyst Report?
Tenaya Therapeutics (TNYA) Ratios
3,507 Followers
Tenaya Therapeutics Ratios
TNYA's free cash flow for Q3 2026 was $1.56M. For the 2026 fiscal year, TNYA's free cash flow was increased by $11.00K and operating cash flow was $-17.68M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 6.84 | 4.22 | 4.91 | 7.99 | 11.73 |
| Quick Ratio | 6.84 | 4.22 | 4.91 | 7.99 | 11.73 |
| Cash Ratio | 6.51 | 0.27 | 2.01 | 3.93 | 1.75 |
| Solvency Ratio | -3.47 | -3.79 | -3.71 | -3.23 | -1.80 |
| Operating Cash Flow Ratio | -4.42 | -5.67 | -4.49 | -4.31 | -2.79 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -32.58 | 0.00 | 0.00 | -30.50 |
| Net Current Asset Value | $ 81.93M | $ 40.29M | $ 80.49M | $ 158.19M | $ 217.24M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.07 | 0.11 | 0.07 | 0.05 | 0.05 |
| Debt-to-Equity Ratio | 0.09 | 0.15 | 0.09 | 0.06 | 0.06 |
| Debt-to-Capital Ratio | 0.08 | 0.13 | 0.08 | 0.06 | 0.05 |
| Long-Term Debt-to-Capital Ratio | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.19 | 1.29 | 1.22 | 1.15 | 1.14 |
| Debt Service Coverage Ratio | 0.00 | -36.96 | 0.00 | 0.00 | -34.45 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.07 | 0.02 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.07 | 0.16 | 0.17 | 0.34 | 0.38 |
| Net Debt to EBITDA | 1.09 | -0.09 | 0.29 | 0.70 | 0.33 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 97.07% | 95.84% | 94.58% | 98.44% | 99.88% |
| Return on Assets (ROA) | -61.66% | -92.65% | -72.77% | -44.33% | -22.97% |
| Return on Equity (ROE) | -73.50% | -119.68% | -89.00% | -50.81% | -26.11% |
| Return on Capital Employed (ROCE) | -70.98% | -111.53% | -88.77% | -49.32% | -24.69% |
| Return on Invested Capital (ROIC) | -69.39% | -108.62% | -86.25% | -48.56% | -24.52% |
| Return on Tangible Assets | -61.66% | -92.65% | -72.77% | -44.33% | -22.97% |
| Earnings Yield | -83.24% | -91.62% | -51.90% | -137.26% | -9.29% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 2.36 | 1.64 | 1.54 | 0.91 | 0.38 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -154.94 | -222.50 | -236.55 | -401.24 | -972.21 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 154.94 | 222.50 | 236.55 | 401.24 | 972.21 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.45 | -1.07 | -1.38 | -2.33 | -1.47 |
| Free Cash Flow Per Share | -0.45 | -1.08 | -1.40 | -2.79 | -2.08 |
| Dividend Paid and CapEx Coverage Ratio | -110.46 | -88.29 | -82.38 | -5.06 | -2.42 |
| Capital Expenditure Coverage Ratio | -110.46 | -88.29 | -82.38 | -5.06 | -2.42 |
| Operating Cash Flow Coverage Ratio | -6.30 | -6.65 | -8.22 | -6.92 | -3.87 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -63.29% | -75.46% | -43.21% | -138.80% | -10.98% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.21 | -1.09 | -1.93 | -0.73 | -10.76 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.88 | 1.31 | 1.71 | 0.37 | 2.81 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.58 | -1.33 | -2.31 | -0.72 | -9.11 |
| Price-to-Operating Cash Flow Ratio | -1.59 | -1.34 | -2.34 | -0.86 | -12.87 |
| Price-to-Earnings Growth (PEG) Ratio | 0.02 | 0.05 | 0.05 | -0.01 | -0.13 |
| Enterprise Value Multiple | -0.23 | -1.27 | -1.78 | -0.09 | -11.06 |
| Enterprise Value | 19.12M | 130.58M | 205.81M | 9.92M | 760.04M |
| EV to EBITDA | -0.23 | -1.27 | -1.78 | -0.09 | -11.06 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -0.28 | -1.43 | -1.99 | -0.08 | -8.84 |
| EV to Operating Cash Flow | -0.28 | -1.44 | -2.02 | -0.10 | -12.50 |
| Tangible Book Value Per Share | 0.81 | 1.09 | 1.89 | 5.43 | 6.75 |
| Shareholders’ Equity Per Share | 0.81 | 1.09 | 1.89 | 5.43 | 6.75 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.59 | -1.31 | -1.68 | -2.76 | -1.76 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.75 | 0.81 | 0.82 | 0.84 | 0.84 |
Currency in USD

